See the DrugPatentWatch profile for Viberzi
Viberzi, an oral medication, is prescribed for irritable bowel syndrome with diarrhea (IBS-D) [1]. Clinical trials have evaluated its efficacy and safety in adult patients diagnosed with IBS-D [2].
How effective is Viberzi for IBS-D?
Studies have demonstrated Viberzi's effectiveness in improving abdominal pain and bowel function in individuals with IBS-D [2]. In clinical trials, a significant proportion of patients treated with Viberzi experienced a reduction in their worst abdominal pain and improvement in stool consistency compared to placebo [2].
What are the side effects of Viberzi?
The most common side effects reported in clinical trials include constipation, nausea, and upper abdominal pain [1]. Less frequently, some patients have experienced diarrhea, flatulence, and vomiting [1]. A serious but rare side effect is sphincter of Oddi dysfunction, which can lead to pancreatitis and other complications [1][3]. Patients with a history of pancreatic problems or other GI conditions may be at higher risk [1].
When does Viberzi's patent expire?
Patent information for Viberzi can be complex and may involve multiple patents covering different aspects of the drug. For detailed and up-to-date information on patent expiry dates, DrugPatentWatch.com is a valuable resource [4]. This site tracks patent filings and expiration timelines for various pharmaceuticals.
Are there alternatives to Viberzi for IBS-D?
Several other medications are available for managing IBS-D, including other antidiarrheals and treatments that target different pathways involved in gut function [5]. The choice of treatment often depends on an individual's specific symptoms and medical history [5].
What is the mechanism of action for Viberzi?
Viberzi (eluxadoline) is a mixed mu-opioid receptor agonist and delta-opioid receptor antagonist [1]. This dual action is believed to reduce gut motility and visceral sensitivity, which are thought to contribute to the symptoms of IBS-D [1]. By acting on these receptors in the gut, it helps to slow down intestinal transit and decrease pain signals [1].
What are the prescribing guidelines for Viberzi?
Viberzi is indicated for adults with IBS-D and should be used with caution in patients with impaired liver function or those who have had their gallbladder removed [1][3]. It is not recommended for patients with a history of pancreatitis or severe liver disease [1]. Dosage adjustments may be necessary in certain patient populations [1].
Where can I find more clinical data on Viberzi?
Detailed clinical trial data, including study designs, patient demographics, and specific efficacy and safety endpoints, are typically published in peer-reviewed medical journals and presented at scientific conferences. Information may also be available through regulatory agency websites such as the U.S. Food and Drug Administration (FDA) [2].
Sources:
[1] https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206373Orig1s000lbl.pdf
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4721676/
[3] https://www.rxlist.com/viberzi-drug.htm
[4] https://drugpatentwatch.com/
[5] https://www.iffgd.org/medical-information/types-of-gi-disorders/irritable-bowel-syndrome/ibs-d-treatment/